BioSpace News Archive

Danaher Corporation announced results for the quarter ended April 3, 2020.

RAINER M. BLAIR TO SUCCEED THOMAS P. JOYCE, JR. AS PRESIDENT AND CEO IN SEPTEMBER 2020 [06-May-2020] WASHINGTON , May 6, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (“Danaher” or “the Company”) today announced that Executive Vice President, Rainer M. Blair , will succeed Thomas P. Joyce Jr. as President and Chief Executive Officer and as a member of the Co

Veracyte, Inc. announced financial results for the first quarter ended March 31, 2020 and provided an update on recent business progress.

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced full results of operations for the first quarter of 2020, with net sales and adjusted earnings per share (EPS) in line with the preliminary results announced on April 9, 2020.

Bruker Corporation announced financial results for its first quarter ended March 31, 2020.

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:

Vapotherm, Inc., a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the commencement of a proposed public offering of $75 million of its shares of common stock.

Houston, TX (May 5, 2020) – Pulmotect, Inc., a clinical-stage biotechnology company, has received approval from the U.S. Food & Drug Administration (FDA) to initiate two COVID-19 Phase-2 clinical trials of its innate immune stimulating drug PUL-042.

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it will host a conference call on May 14, 2020 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2020.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported business highlights and financial results for the first quarter of 2020.